Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery
Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study analyzes the safety and efficacy of off-label Subconjunctival Injection of
bevacizumab (Avastin) versus 0.02% mitomycin C (MMC) for preventing bleb failure following
glaucoma filtration surgery.